Weight Watchers Partners with LillyDirect to Expand GLP-1 Access, Bolstering Turnaround Efforts
WW sits 93% above its 52-week low of $8.365.
Summary
WW International's Med+ program, which integrates GLP-1 medication access with clinical and behavioral support, is now accessible through Eli Lilly's LillyDirect platform. This partnership is a significant strategic move for WW, directly connecting its services to patients seeking GLP-1 treatments. The company has recently faced substantial challenges, including a 9.6% revenue decline and a 22.6% drop in subscribers in Q1 2026, as well as leadership changes and activist investor involvement. This collaboration with a major pharmaceutical player like Eli Lilly could be crucial for driving subscriber growth and revenue recovery for WW.
At the time of this announcement, WW was trading at $16.13 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $161.3M. The 52-week trading range was $8.37 to $46.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.